Enlivex Therapeutics (ENLV), which is listed on the Nasdaq and the Tel Aviv Stock Exchange, continues to trade without any interruption. Due to a technical error, TipRanks mistakenly reported that the company, which develops a drug pipeline for the treatment of autoimmune and inflammatory conditions, had suspended trading. TipRanks unequivocally retracts that erroneous report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Enlivex stock rose by .96% in Friday’s trading, and has traded sideways for the past three months. The company met earnings estimates in its past two reports.
